Neovacs S.A. (Euronext Growth Paris: ALNEV)

https://www.neovacs.fr

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. *

	Start	2010-05-21 existent
	Group	Neovacs (Group)
	Industry	therapeutic vaccine
	Industry 2	TNF-Kinoid
	Person	Sieler, Miguel (Neovacs 201310 CEO before Bayer France CEO at Bayer since 1975)
	Person 2	Fanneau de la Horie, Guy-Charles (Pherecydes Pharma 201602– CEO before PathoQuest + Neovacs + Biogen)

	Region	Paris
	Country	France
	Street	3–5 Impasse Reille
	City	75014 Paris
	Tel	+33-1-5310-9300
		Address record changed: 2024-01-05

Basic data	Employees	B: 11 to 50 (2014-11-01)
	Currency	EUR
	Annual sales	394,000 (revenues (2016) 2016-12-31)
	Profit	-13,932,000 (2016-12-31)
	Cash	3,900,000 (2016-12-31)

		* Document for »About Section«: Neovacs S.A.. (2/22/18). "Press Release: Neovacs Strengthens Its Intellectual Property in the USA". Paris & Boston, MA.

		Record changed: 2024-02-12